Mount Sinai Study Finds One Quarter of WTC Responders Continue to Have Lung Function Impairment
Find out more here
Dr. Gwen Skloot discusses the link between asthma and obesity in The Daily News feature The Daily Check Up.
Critical Care Medicine
MD, New York University
Internship, Internal Medicine
Mount Sinai Hospital
Residency, Internal Medicine
Mount Sinai Hospital
Fellowship, Pulm & Critical Care
Johns Hopkins Hospital
Airway Responsiveness in Asthma
Our laboratory focuses on clinical asthma studies. We hypothesize that hyperresponsiveness is caused by impairment in the ability of inspiration to stretch airway smooth muscle (ASM) -- i.e. impaired bronchodilation. This hypothesis is supported by our finding that sensitivity to the constrictor agent Methacholine is the same in normals and asthmatics when challenge is conducted without deep breaths. It is also known that deep inspiration (DI) prior to a constrictor agent is bronchoprotective in normal subjects. We have shown that this effect relates to inspiratory velocity, i.e. a fast DI is more bronchoprotective than a slow DI. We speculate that in healthy subjects, DI stretches ASM and breaks cross bridges and that cross bridge breakage is enhanced with increased inspiratory velocity. In asthmatics, inflammation may impair this ability. Further protocols will focus on the mechanism of the impaired response to DI in asthma in order to ultimately develop interventions to treat this aspect of hyperresponsiveness.
We have developed an in vitro model to test similar ideas. We hypothesize that stretching guinea pig (GP) tracheal smooth muscle releases a humoral "relaxant" factor [i.e. stretch-induced relaxation (SIR) involves a receptor-mediated mechanism]. The analogous in vivo situation may be the release of a "bronchodilating" substance when a normal subject takes a deep breath. This bronchodilating substance may be decreased in asthma. We have demonstrated that GP tracheal smooth muscle does relax when stretched; this relaxation is enhanced post-carbachol. We have characterized this relaxation response by pharmacokinetic studies. Additional characterization studies are focused on inhibiting the SIR response with agents such as beta-blockers, indomethacin, etc. We have shown that after induction of airway inflammation, the SIR response is reduced. Future protocols will address the mechanism of this reduced response and the relevance to human asthma.
A Multi-Centre Open-Label Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial
The purpose of this study is to allow subjects to continue to receive the study treatment they received in the existing GlaxoSmithKline (GSK) study MEA115661. The study medication mepolizumab is not approved by the Food and Drug Administration (FDA) for doctors to treat patients ...
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosinophils
The purpose of this study is to compare an investigational drug called reslizumab with placebo (a substance that looks like an active drug but has no drug or other active ingredient) to find out if it is safe and can help people with uncontrolled asthma and with a type of asthma ...
Study MEA117106: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients
The purpose of this study is to test an investigational (experimental) study medicine, called mepolizumab, to see if it is safe, and to see how effective it is at preventing COPD or Chronic Obstructive Pulmonary Disease exacerbations ('flare ups' of the condition). Mepolizumab is...
A Phase II, Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Oral Corticosteroid-Sparing Effect of Lebrikizumab in Patients with Severe Corticosteroid Dependent Asthma
The purpose of this study is to find out what effects, good or bad, lebrikizumab has on the subject and their asthma. Lebrikizumab is an experimental drug, which means that health authorities have not approved it for the treatment of asthma or any other disease. Subjects...
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Skloot did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.